Clinical evaluation of valsartan and metoprolol tartrate in treatment of diabetic nephropathy with positive β1-adrenergic and anti-angiotensin Ⅱ type 1 receptor antibody
- Author:
- No author available
- Journal Title:
- Chinese Medical Journal
- Issue:
- 19
- DOI:
- 10.3760/cma.j.issn.0366-6999.2012.19.033
- Key Word:
- diabetic nephropathy;β1-adrenergic receptor;anti-angiotensin Ⅱ type 1 receptor;valsartan;metoprolol tartrate
Abstract： Background Studies have confirmed that angiotensin Ⅱ receptor blocker (ARB) and angiotensin converting enzyme inhibitors (ACEI) in the treatment of diabetic nephropathy (DN) has special advantages.We observed the effects of valsartan and metoprolol tartrate hydrchloride in treatment of DN patients with positive β1-adrenergic and anti-angiotensin Ⅱ type 1 (AT1) receptor antibody.Methods The epitopes of the second extracellular loop of β1 receptor (197-222) and AT1 receptor (165-191),were synthesized and used respectively to screen serum autoantibodies from patients with DN (n=371,group A),diabetes mellitus (DM) without renal failure (n=107,group B) and healthy blood donors (n=47,control,group C) by enzyme-linked immunosorbent assay (ELISA).Metoprolol tartrate 25-50 mg,three times per day,valsartan 160 mg,once a day,aspirin 100 mg,once a day,and nitrendipine 10-20 mg,three times per day,were given to DN patients with positive or negative autoantibodies.The cystatin C level and 24-hour urinary protein were measured before and after treatment.Results In DN patients,the positive rate of the autoantibodies against β1 receptors and AT1 receptor was 47.7％ and 51.5％,respectively,which were significantly higher than those in DM patients and healthy controls (all P ＜0.01).Patients with anormalous cystatin C had higher positive rates of the autoantibodies than patients with normal cystatin C.Valsartan and metoprolol tartrate reduced proteinuria significantly (P ＜0.01) in DN patients with positive autoantibodies.Conclusions The findings suggest that these autoantibodies against β1 and AT1-receptor may play important roles in the pathogenesis of DN.Valsartan and metoprolol tartrate are effective and safe in the treatment of DN.Chin Med J 2012; 125(19):3543-3547
- [1]周子华,廖玉华,李留东,等.抗α1-肾上腺素受体抗体介导大鼠心室重塑的免疫机制[J].2005,(9).
- [2]Duckworth W,Abraira C,Moritz T,etc.Glucose control and vascular complications in veterans with type 2 diabetes.[J].2009,360(22 Suppl.).
- [3]Kruse I,Schon B,Muller J,etc.Decreased oxidative stress in patients with idiopathic dilated cardiomyopathy one year after immunoglobulin adsorption.[J].2001,38(1).
- [4]T L, Goodfriend,M E, Elliott,K J, Catt.Angiotensin receptors and their antagonists.[J].1996,334(25).
- [5]Holman RR,Paul SK,Bethel MA,etc.10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes.[J].2008,359(15).
- [6]Cooper M,de-Galan BE,MacMahon S,etc.Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.[J].2008,358(24).
- [7]Zelmanovitz T.Diabetic Nephropathy: Diagnosis, Prevention, and Treatment.[J].2005,28(1).
- [8]Lewis JB,Lewis EJ,Parving HH,etc.Aliskiren combined with losartan in type 2 diabetes and nephropathy.[J].2008,358(23).
- [9]Riddle MC.Effects of intensive glucose lowering in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.[J].2010,122(8).
- [10]Henegar JR,Henegar LK,Tyagi SC,etc.Functional and structural changes in the kidney in the early stages of obesity.[J].2001,12(6).
- [11]Grosse Y,Spielhagen T,Staudt A,etc.Removal of cardiodepressant antibodies in dilated cardiomyopathy by immunoadsorption.[J].2002,39(4).
- [12]G.C. Viberti,R.W. Bilous,D. Mackintosh,etc.Monitoring glomerular function in diabetic nephropathy: A prospective study[J].1983,74(2).
- [13]Gouwy M,Struyf S,Verbeke H.CC chemokine ligand-2 synergizes with the nonchemokine G protein-coupled receptor ligand fMLP in monocyte chemotaxis, and it cooperates with the TLR ligand LPS via induction of CXCL8.[J].2009,86(3).
- [14]Sarafidis PA,Kanaki AI,Stafylas PC,etc.Effects of renin-angiotensin system blockers on renal outcomes and all-cause mortality in patients with diabetic nephropathy: an updated meta-analysis.[J].2008,21(8).
- [15]Almeida JC,Zelmanovitz T,Vaz JS,etc.Sources of protein and polyunsaturated fatty acids of the diet and microalbuminuria in type 2 diabetes mellitus.[J].2008,27(5).
- [16]Loke YK,Singh S,Furberg CD.Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis.[J].2009,180(1).
- [17]Colhoun HM,Durrington PN,Betteridge DJ.Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS).[J].2009,54(5).
- [18]Pan Y,Guo LL,Jin HM.Low-protein diet for diabetic nephropathy: a meta-analysis of randomized controlled trials.[J].2008,88(3).
- [19]Wang GB,Jiang JP,Zhang X,etc.Efficacy and safety of benazepril for advanced chronic renal insufficiency.[J].2006,354(2).
- [20]Druey KM,Bansal G,Kuehn HS,etc.RGS13 controls g protein-coupled receptor-evoked responses of human mast cells.[J].2008,181(11).
- [21]Parving HH,Lehnert H,Brochner-Mortensen J,etc.The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.[J].2001,345(12).
- [22]Inselmann G,Boege F,Jahns R,etc.Activating beta-1-adrenoceptor antibodies are not associated with cardiomyopathies secondary to valvular or hypertensive heart disease.[J].1999,34(5).
- [23]Gross JL.Urinary Albumin Excretion Rate Is Associated With Increased Ambulatory Blood Pressure in Normoalbuminuric Type 2 Diabetic Patients.[J].2005,28(7).
- [24]Fioretto P,Caramori ML,Mauer M.The kidney in diabetes: dynamic pathways of injury and repair. The Camillo Golgi Lecture 2007.[J].2008,51(8).